2
|
Rueda A, Provencio M, Abrio M, Gómez-Codina J, Llanos M, Delgado J, Rifá J, Sabin P, Vélez de Mendizabal E, Baz V. Rituximab maintenance after R-CHOP in the first-line treatment of follicular lymphoma: A GOTEL phase II trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19502 Background: Rituximab maintenance have demonstrated improvements in progression-free and overall survival in relapsed patients with follicular lymphoma (FL). Ongoing trials are evaluating the benefit of rituximab maintenance following treatment of therapy-naive patients (pts) treated with rituximab-containing chemoinmunotherapy induction regimens. Methods: The current study evaluated the activity and toxicity of rituximab maintenance after chemoinmunotherapy in the first line treatment of advanced-stage FL. Pts with advanced stage FL were eligible. The induction treatment consisted in 8 courses of chemoinmunotherapy with R-CHOP (rituximab 375 mg/m2; cyclophosphamide 750 mg/m2; doxorubicin 50 mg/m2 and vincristine 2 mg). Pts entering a complete (CR) or partial remission (PR) received maintenance with 6 doses of rituximab (375 mg/m2/d) to be given every two months after the end of induction therapy. Results: From December 2004 to November 2006, 52 pts were included. Median age was 52 years (range, 36–85) and 26 pts were women. At baseline 32 (62%) pts had stage IV and 20 (38%) stage III. According to the Follicular Lymphoma International Prognostic Index (FLIPI), 8 pts (15%) had low risk disease, 24 pts (46%) intermediate risk, and 20 pts (39%) high risk disease. Six (12%) pts did not receive maintenance (3 pts progressed during induction, 2 pts refused maintenance and 1 pt had severe toxicity to induction). Of the 46 pts included in the maintenance phase, 32 (69%) were in CR/CRu and 14 pts (31%) in PR after induction therapy. Rituximab was well tolerated in the maintenance phase. Only 5 pts didn´t receive the 6 scheduled courses (toxicity: 1; progressive disease: 2; cardiovascular events: 2). Grade 3–4 toxicity occurred as follow: neutropenia in 4 pts (9%), and fever in 1 pt (2%). No severe infections were seen. After maintenance, 40 (87%) pts were in CR/CRu, 4 pts (9%) in PR and 2 (4%) progressed. With a median follow-up of 27 months, progression-free and overall survival at 30 months were 82% and 92%, respectively. Conclusions: Rituximab maintenance after first-line R-CHOP is safe and increase the complete remission rate obtained in the induction phase. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Rueda
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - M. Provencio
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - M. Abrio
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - J. Gómez-Codina
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - M. Llanos
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - J. Delgado
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - J. Rifá
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - P. Sabin
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - E. Vélez de Mendizabal
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | - V. Baz
- Hospital Costa del Sol, Marbella, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital La Fe, Valencia, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Son Dureta, Mallorca, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital San Millán, Logroño, Spain; Grupo Oncológico para el Tratamiento y Estudio delos Linfomas; Hospital Juan Ramón Jiménez, Huelva, Spain
| | | |
Collapse
|
4
|
Rueda A, Sabin P, Rifá J, Llanos M, Gómez-Codina J, Lobo F, García-Arroyo R, Herrero J, Provencio M, Jara C. R-CHOP-14 in patients with diffuse large-B-cell lymphoma (DLBCL) younger than 70 years: A multicentric and prospective study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7592 Background: Several studies have shown that the addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisona), or shortening the interval between cycles of chemotherapy to two weeks, improves survival of patients with DLBCL. These studies prompted our group (GOTEL) to evaluate in a prospective study, the feasibility and efficacy of R-CHOP-14 in patients (pts) with DLBCL. Methods: Patients (younger than 70 years) with stage II bulky, III or IV DLBCL, and no significant co-morbidities were included in the study. R was administered on day 1 before chemotherapy. R-CHOP was recycled every 14 days. No antimicrobial prophylaxis was administered. All pts received filgrastim (5 μg/kg) from day +3 to +10. Pts received 6 cycles if CR was achieved after 3 cycles; those in PR, and those pts with bone marrow disease at diagnosis, received 8 cycles. Involved field radiation therapy was permitted for pts with stage II bulky disease. Results: From May 2002 to august 2004, 77 pts were included. Median age was 54 years (range, 15–70); 55 patients were younger than 60 years. According to the age adjusted International Prognostic Index (aaIPI), 13 pts (17%) had low risk disease, 27 pts (35%) low-intermediate risk, 29 pts (38%) high-intermediate risk, and 8 pts (10%) high risk disease. Grade 3–4 toxicity occurred as follow: neutropenia in 15 pts (19%), anaemia in 7 pts (9%), thrombocytopenia in 4 pts (5%), mucositis in 4 pts (5%) and peripheral neurotoxicity in 4 pts (5%). Ten pts were hospitalized (febrile neutropenia: 8 cases, one case of gastric perforation and one pulmonary embolism). After therapy, 61 pts (79%) achieved a CR/CRu (C.I. 95%: 57%-90%) and 14 pts (18%) a PR. 2 pts (3%) had refractory disease. With a median follow-up of 20 months, progression-free and overall survival at 24 months were 68% and 87%, respectively. Conclusions: Administration of R-CHOP-14 (with filgrastim support) is feasible and effective in patients younger than 70 years. [Table: see text]
Collapse
Affiliation(s)
- A. Rueda
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - P. Sabin
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - J. Rifá
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - M. Llanos
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - J. Gómez-Codina
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - F. Lobo
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - R. García-Arroyo
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - J. Herrero
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - M. Provencio
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| | - C. Jara
- Grupo Oncologico Para el Tratamiento y Estudio de los Linfomas, Malaga, Spain
| |
Collapse
|